Literature DB >> 19751872

Stereotactic radiosurgery and stereotactic radiotherapy in the treatment of skull base meningiomas.

John M McGregor1, Atom Sarkar.   

Abstract

Meningiomas are the most common nonglial brain tumors. They tend to be slow growing and benign and can reach substantial sizes before becoming symptomatic. Complete surgical resection of intracranial meningiomas remains the treatment of choice. Location of a meningioma within the cranial vault may make complete surgical resection unlikely; tumors arising from the dura of the skull base are particularly challenging. Advances in radiation therapy, including stereotactic techniques, can expand the options for treatment available in these situations. They may be used as adjuncts to surgery or as alternative modalities in the treatment of these complex tumors.

Entities:  

Mesh:

Year:  2009        PMID: 19751872     DOI: 10.1016/j.otc.2009.04.010

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN: 0030-6665            Impact factor:   3.346


  4 in total

1.  A review of stereotactic radiosurgery practice in the management of skull base meningiomas.

Authors:  Elena Vera; J Bryan Iorgulescu; Daniel M S Raper; Karthik Madhavan; Brian E Lally; Jacques Morcos; Samy Elhammady; Jonathan Sherman; Ricardo J Komotar
Journal:  J Neurol Surg B Skull Base       Date:  2014-03-12

2.  Skull base meningiomas: neurological outcome after microsurgical resection.

Authors:  Judith Scheitzach; Karl-Michael Schebesch; Alexander Brawanski; Martin A Proescholdt
Journal:  J Neurooncol       Date:  2013-11-21       Impact factor: 4.130

3.  Major intratumoral hemorrhage of a petroclival atypical meningioma: case report and review of literature.

Authors:  Erwin Zeta Mangubat; Richard W Byrne
Journal:  Skull Base       Date:  2010-11

4.  Long-term evaluation of the effect of hypofractionated high-energy proton treatment of benign meningiomas by means of (11)C-L-methionine positron emission tomography.

Authors:  Mats Ryttlefors; Torsten Danfors; Francesco Latini; Anders Montelius; Erik Blomquist; Olafur Gudjonsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-28       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.